Studies indicate that NNMT inhibition by compounds such as 5-Amino-1MQ can result in reduced fat mass and improved insulin resistance
Synergistic Formulation: This unique lipo-c with added b12 blend combines Methionine, Inositol, and Choline (MIC) with structural cyanocobalamin to support multi-pathway cellular analysis
This content is meant for registered healthcare professionals only.
Clinical research established that the most commonly effective range is 250-500 mcg (0.25-0.5 mg) administered once daily via subcutaneous injection
The non-coded amino acid residues incorporated at positions 2, 20, and 13 provide resistance to enzymatic degradation while maintaining receptor-binding affinity across all three target receptors
Phase 1 human trials have been registered in some geographies Published human efficacy data at the level of a completed, results-reported phase 2 study are not yet a settled part of the dataset Commercial development is active but has not produced a near-term approval path Patients and clinicians tracking 5-amino-1MQ should monitor ClinicalTrials.gov and peer-reviewed publications for current status
